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ABSTRACT
Background. The incidence of ductal carcinoma in situ
(DCIS) is increasing with the use of screening mammog-
raphy, and approximately 30% of all women diagnosed
with DCIS are treated by mastectomy. There is increasing
use of a skin-sparing mastectomy (SSM) approach to sur-
gically excise DCIS as this facilitates immediate breast
reconstruction. The rates of locoregional recurrence (LRR)
after simple mastectomy performed for pure DCIS are
historically reported as 1%; however, international data
suggest that LRR after SSM may be higher.
Methods. To determine our rates of LRR and compare the
effect of the type of mastectomy performed, we undertook
a retrospective review of all patients who underwent a
mastectomy for pure DCIS at our institution between 2000
and 2010.
Results. In total, 199 patients underwent a mastectomy for
pure DCIS (with eight local recurrences), all of which were
invasive ductal carcinoma. The recurrences all occurred
after SSM, which was associated with a higher 5-year LRR
of 5.9% (5/102) compared with 0% in the simple mastec-
tomy group (0/97; p = 0.012), log-rank. Univariate
analysis showed the two factors that predicted the risk of
recurrence were a young age at mastectomy and close or
involved margins.
Conclusions. These data highlight the importance of
achieving clear margins, especially in young women with
estrogen receptor-negative DCIS who have a higher risk of
invasive recurrence. Women undergoing a mastectomy for
DCIS should be counseled as to the importance of
achieving clear margins and the potential increased need
for further excision, post-mastectomy radiotherapy and
post-reconstruction mammography in order to prevent LRR
after SSM.
Ductal carcinoma in situ (DCIS) is a pre-invasive form
of breast cancer where malignant cells are confined within
the ductal basement membrane.1 Its incidence has
increased with the introduction of screening mammogra-
phy and it accounts for 21% of screen-detected
malignancies in the UK.2 Surgical excision involves breast-
conserving surgery in the form of a wide local excision
(WLE) or removal of the entire breast by mastectomy.
Mastectomy is indicated where there is extensive DCIS to
breast size which does not allow for a cosmetically or
surgically acceptable WLE, or in the presence of multifocal
disease.1 According to The Second All Breast Cancer
Report, 38% of non-invasive breast cancers were treated by
mastectomy in 2007.3
A simple mastectomy was traditionally performed
whereby the entire breast is removed with a large ellipse of
overlying skin. Increasing use of skin-sparing mastectomy
(SSM) facilitates immediate breast reconstruction by pre-
serving the patients’ skin coverage with improved aesthetic
and psychological outcome.4,5 SSM involves excision of
the breast via a smaller elliptical incision, resulting in less
scarring and fewer surgical procedures.4
The larger surface area of SSM skin flaps increases the
potential to leave residual breast tissue. Achieving the ideal
mastectomy flap that is thin enough to remove all breast
tissue but thick enough to keep subdermal vessels and
support an adequate blood supply is difficult.6 Histological
studies have shown that this plane is absent in 44% of cases
and its thickness varies from 0 to 29 mm, with a median of
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10 mm.7,8 A mastectomy flap of 4–5 mm led to flap
necrosis rates of 17%, whereas others reported less than 5%
with flaps thicker than 5 mm.9,10 Higher rates of locore-
gional recurrence (LRR) after SSM were initially reported
for invasive cancer11 but were not confirmed in a subse-
quent meta-analysis of LRR (4% in simple mastectomy vs.
6.2% in SSM).12 This analysis encompassed all forms of
breast cancer, with no subgroup analysis in DCIS.12
LRR after mastectomy for DCIS has historically been
demonstrated as low, with the UK SLOANE audit reporting a
1% LRR,13 and a meta-analysis incorporating 1574 patients
demonstrating an LRR of 1.4%.14 DCIS is associated with
less clinically apparent disease, making identification of
lesions intraoperatively more difficult.1 There is often more
widespread multi-focal disease with a greater chance of a
separate DCIS foci away from the primary lesion than in
invasive ductal carcinoma (IDC).15 This emphasizes the
importance of removing all breast tissue during a mastectomy
as residual parenchyma may contain another focus of
DCIS.5,15 Cao et al. removed an additional superficial margin
directly over the tumor in 168 patients. Thirty-eight percent
had a positive superficial specimen margin, 13 (20%) of
whom had residual carcinoma in the additional biopsy. Fac-
tors associated with a positive flap biopsy were the presence
of extensive DCIS and a thicker superficial flap biopsy.16 In
2007, 27% of patients undergoing a mastectomy for DCIS had
an SSM with immediate breast reconstruction compared with
10% in invasive disease.3 The higher rates of SSM use in
DCIS are to be expected as these patients are unlikely to
require adjuvant radiotherapy.13 Despite SSMs increasing use
in DCIS, there are little data on oncological outcomes in
simple mastectomy compared with SSM. Emerging data
from the US highlight that LRR after SSM for DCIS is high, at
5%.17 Higher LRR has been reported in the UK, with a
15-year retrospective review of screen-detected lesions in the
West Midlands demonstrating a 3.1% 5-year LRR and an 8%
15-year LRR.18
We aimed to determine our LRR after mastectomy for
DCIS, comparing SSMs and simple mastectomies and
evaluating which factors predicted LRR.
PATIENTS
We undertook a retrospective review of all patients who
had a mastectomy for pure DCIS at the University Hospital
of South Manchester between 2000 and 2010, after hospital
ethical approval was obtained.
The operation notes were reviewed to collect data on the
type of mastectomy, the reconstructive strategy used, and
the type of axillary surgery.
Pathological reports were reviewed and data collected
on histological type, grade, size of DCIS, and margin
status. The presence or absence of microinvasion, lym-
phovascular invasion, and comedonecrosis was recorded,
and the available molecular phenotype information,
including estrogen receptor (ER) status, progesterone
receptor (PR) status, and human epidermal growth factor
receptor 2 (HER2) status, for those patients recruited to
clinical trials was also recorded.
Clinical notes were reviewed to evaluate the method of
presentation, use of adjuvant therapy, and follow-up data.
When recurrences did occur, we gathered information on
the location of recurrence, which was recorded as local,
regional or metastatic, and subsequent treatment and
histopathological data.
Follow-Up
All patients underwent clinical examination, as well
contralateral mammography, annually for a minimum of
5 years before returning to the National Health Service
(NHS) breast screening program.
Local recurrence was classified as ipsilateral skin, sub-
cutaneous or chest wall recurrence, while contralateral
recurrence was defined as contralateral breast parenchyma
disease, both of which were proven by histopathological
biopsy. Regional recurrence was classified as ipsilateral
regional lymph node recurrence, either axillary, supra-
clavicular or internal mammary clearance, while metastatic
recurrence was defined as any recurrence distant to the
aforementioned sites. We included all patients who
underwent a mastectomy for pure DCIS, and those indi-
viduals who had microinvasion or lobular carcinoma in situ
(LCIS) were also included. All patients who had a definite
invasive element and lymph involvement were excluded.
Statistical Analysis
The data were collected and analyzed using SPSS ver-
sion 22.0 (IBM Corporation, Armonk, NY, USA). The
Student’s t test was used to compare continuous variables
between two groups, and the Chi-square test was used to
compare categorical variables. Survival was evaluated
using Kaplan–Meier survival curves and the log-rank test
was used to compare survival between the two groups. As
there were only eight recurrences, we had insuffi-
cient numbers for a robust regression analysis. The
conventional 5% significance level was used (Fig. 1).
RESULTS
In total, 199 patients underwent a mastectomy for DCIS
between January 2000 and December 2010, with a median
follow-up time of 65 months (range 0–152).
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SSM was undertaken on 102 patients and 97 had a
simple mastectomy. Table 1 highlights the different
demographic and histopathological features, as well as ER
status, between the two groups.
Sixty-eight percent of patients presented with a screen-
detected lesion and 32% presented symptomatically. SSM
patients were younger, with a mean age of 53 years com-
pared with 61 years in the simple mastectomy group
(p\ 0.01). No difference in the size of DCIS excised, the
percentage of high-grade DCIS, or margin involvement
was found between the SSM (31%) and simple mastectomy
(26%) groups (Table 1). Patients undergoing simple
mastectomy were more likely to be ER-negative, and
95.7% of ER-negative patients were HER2 positive.
Type of Reconstruction
Of 102 patients treated by SSM, none were nipple-sparing
mastectomies, 65 (63.7%) underwent immediate one-stage
reconstruction, and 37 (36.3%) had insertion of a tissue
expander followed by definitive reconstruction (Table 2).
Pathology
LCIS was present in conjunction with DCIS in 13
patients, and definite or possible microinvasion was present
in 19 patients.
Recurrence
During the 10-year analysis period, eight LRRs were
noted, all in the SSM group. There were no local recur-
rences after simple mastectomy. Kaplan–Meier analysis
demonstrated that overall 5-year LRRs were 3.1% at
5 years and 5.6% at 8 years. LRR rates were higher in the
SSM group, which had a 5.9% 5-year LRR compared with
0% in the simple mastectomy group (p = 0.012, log-rank).
Univariate analysis identified two factors that predicted
risk of recurrence: a young age at mastectomy (\50 years
of age) and close (\2 mm) or involved margins. Screen-
detected LRR was 4.5% (6/132), similar to 3.4% (2/59) for
symptomatic presentation. In general, high-grade and ER-
negative tumors were more likely to recur, however there
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FIG. 1 Kaplan–Meier curve comparing local recurrence after simple
mastectomy and SSM. SSM skin-sparing mastectomy, LRR locore-
gional recurrence
TABLE 1 Characteristics of the simple mastectomy and SSM patient groups
Simple (n = 97) SSM (n = 102) p-Value
Mean age, years (range) 61 (40–81) 53 (33–71) \0.01a
Symptomatic presentation 28 36 0.72b
Size of DCIS, mm (range) 39 (2–130) 38 (1–125) 0.80a
High-grade 28 33 0.40b
Involved margin,\2 mm 26 31 0.38b
ER-negative 43 28 0.03b
HER2-positive 87 67 0.06b
Ipsilateral 5-year LRR 0 5.9 0.01c
Contralateral 5-year LRR 4.8 3.2 0.68c
Data are expressed as percentages unless otherwise specified
SSM skin-sparing mastectomy, DCIS ductal carcinoma in situ, ER estrogen receptor, HER2 human epidermal growth factor receptor, LRR
locoregional recurrence
a Student’s t test
b Chi-square test
c Log-rank
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Contralateral Recurrence
The 5-year contralateral recurrence rate was 4.2%, rising
to 8.5% at 8 years. Interestingly, the 5-year ipsilateral
recurrence rate following SSM was higher at 5.9% than the
3.9% contralateral recurrence rate in the SSM group, sug-
gesting that adequacy of excision played a key role.
Analysis of Recurrence
All eight recurrences were IDC and presented as a lump
either on clinical follow-up or symptomatically. Invasive
recurrence represents a loss of local control and therefore
potentially increases patient mortality. Median disease-free
survival time was 55 months (range 15–106 months). Four
of the eight recurrences had surrounding DCIS alongside
the invasive component.
Of the eight recurrences, seven patients had immediate
reconstruction at the time of their SSM. All eight of the
recurrences had re-excision in the form of a WLE and
axillary surgery (see Electronic Supplementary Table 1).
Following recurrence, seven patients had adjuvant radio-
therapy and seven had adjuvant chemotherapy (five with
trastuzumab). Only three patients required endocrine
treatment. One patient died after recurrent disease at
74 months post-surgery.
DISCUSSION
In this large UK series evaluating LRR after mastectomy
for DCIS we found a 3.1% 5-year LRR, consistent with US
results highlighting a higher LRR than the 1–2% histori-
cally quoted.14 LRR after SSM was 5.9% at 5 years
compared with 0% after simple mastectomy. The increas-
ing use of SSM may account for increasing LRR and is
likely to be a consistent pattern with the use of SSM
elsewhere. Previous papers demonstrated that young age at
mastectomy (\50 years), as well as margin status, are
important predictors of LRR.
A retrospective review of 223 patients with DCIS trea-
ted by SSM, with a mean follow-up of 82.3 months,
reported a 5.1% LRR.17 The higher LRR, similar to our
data, was associated with high-grade disease and close
margins as predictors of LRR, with a 10.5% LRR in a
\1 mm margin.17 In this series, six of the seven patients
who recurred had residual breast tissue.17
After mastectomy, many surgeons in the UK are resis-
tant to re-excision if margins, including the anterior (skin)
margin, are involved. Our results highlight the importance
of achieving clear margins and, if close, further surgical
excision is required, even if this is overlying skin.
Fitzsullivan et al. reported 810 patients who underwent
mastectomy for DCIS at the MD Anderson Cancer Center,
with a median follow-up time of 75.6 months and
demonstrating a 1% overall LRR, with a 5% LRR in those
with a margin\1 mm.19 Their SSM group had an LRR of
1.5% (7/469), compared with 0.3% in the simple mastec-
tomy group (1/341), a non-significant difference
(p = 0.09).19 Intraoperative fresh frozen section analysis
was routinely undertaken alongside radiographic imaging,
leading to 14.3% (n = 116) of patients with a close margin
of \3 mm, undergoing intraoperative re-excision, a prac-
tice not used in the UK.19 This re-excision led to a change
in margin status from \3 mm to [3 mm in 103 patients
(89%).19 Of the remaining 13 patients who had a margin of
\3 mm following intraoperative re-excision, nine under-
went a second operation for margin re-excision. This
emphasis on achieving clear margins accounts for the
lower 1% LRR and explains why LRR after SSM was not
significantly higher despite resulting in a closer margin, as
a higher proportion of SSM patients underwent intraoper-
ative re-excision.19 Another study from the same institution
highlighted the benefit of achieving clear margins for
in situ and invasive disease in 1810 patients, demonstrating
a 1% LRR when clear margins were achieved in 99.7% of
patients.20 Increased rates of involved or close margins
(29%) were found in patients undergoing SSM, as opposed
to 12% in simple mastectomies in the study by Sheikh
et al.; however, re-excision to achieve clear margins led to
a low LRR at 28 months of 0.8% after simple mastectomy
and 1.1% after SSM.21
Our unit had high rates of SSM use compared with the
national average and this raises the question as to whether
higher rates of SSM and immediate reconstruction have led
to increased LRR. When undertaking SSM and immediate
reconstruction, surgeons have to balance the further con-
cern of pressure from the reconstruction on skin flaps and
potential necrosis. Kim et al. reviewed recurrence excision
specimens from 10 patients who developed LRR after SSM
for DCIS. Five of the seven patients who underwent
TABLE 2 Reconstructive methods used on 102 patients undergoing
SSM
Type of reconstruction Number of patients LRR
TE then implant 37 (36.3) 1 (2.7)
One stage 65 (63.7) 7 (10.8)
Implant 6 (5.9) 0
Autologous LD flap 49 (48) 4 (8.1)
Autologous TRAM flap 5 (4.9) 2 (40)
Autologous DIEP flap 5 (4.9) 1 (20)
Data are expressed as n (%)
SSM skin-sparing mastectomy, LRR locoregional recurrence, LD
latissimus dorsi, TRAM transverse rectus abdominis muscle, DIEP
deep inferior epigastric perforator
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immediate reconstruction had residual breast tissue.22 The
most commonly involved margin in all three series was the
anterior margin.17,19,23
Post-mastectomy radiotherapy (PMRT) in patients who
had a margin of \2 mm was recommended because of a
16% LRR in one study.23 In a survey of 226 surgeons in the
UK, 19% said they would consider the use of PMRT, with
66% saying margin status was the key factor, but there is
no evidence base for its use nor agreed margin width.24
Further work is required to evaluate differences in LRR
between a margin of 1 and 2 mm to better inform risks of
LRR with margin width and to counsel patients.
Half of the recurrence samples had DCIS associated
with IDC, suggesting that DCIS had been left behind or
that within residual tissue after mastectomy further DCIS
had developed and the absence of radiological follow-up
allowed invasive foci to supervene.
The median disease-free survival time in this study was
55 months, similar to previous reports17,19 and highlighting
the importance of following up patients for at least
60 months. Invasive recurrence represents loss of local
control and requires additional adjuvant treatment with
chemotherapy, radiotherapy ± herceptin, which would not
have been indicated for primary DCIS. Although only one
patient died as a result of invasive recurrence, Bannani et al.
found a 50% mortality rate when disease reoccurred.25
There is no accepted national surveillance policy for the
ipsilateral chest wall or reconstructed breast following
mastectomy for DCIS. The use of screening mammography
when following up patients who have had an SSM with a
transverse rectus abdominis muscle flap reconstruction has
been shown to detect recurrences earlier while the disease
is still in situ.26 However, few data are available to assess
the effectiveness of mammography in patients undergoing
SSM and immediate reconstruction.
Audits of LRR after mastectomy for DCIS have been
large, retrospective, single-institution reviews; however, a
large, prospective, multicenter audit of LRR after SSM is
required. Repeated audit of post-mastectomy LRR has
reduced LRR across all Dutch hospitals to less than 5% at
5 years, and a similar system of surgical quality control of
LRR would likely reduce LRR in the UK.27
Univariate analysis demonstrated higher LRR in
women under 40 years of age, a finding reported by
others, with a 7.5% LRR\40 years of age as opposed to
1.5% [40 years of age.28 Bannani et al. also demon-
strated that patients under 40 years of age had higher
rates of LRR (14.2%) compared with 2.5% in patients
over 40 years of age.25 Symptomatic DCIS and pre-
menopausal women have a higher incidence of ER-
negative disease that recurs earlier, usually within the first
3 years.29 Seven of the eight recurrences occurred in
young women or ER-negative DCIS, and surgeons need
to ensure clear margins and careful surveillance of these
patients (Table 3).
CONCLUSIONS
Surgeons must achieve clear margins and consider re-
excision, including overlying skin, following SSM, par-
ticularly in young women with high-grade and ER-negative
DCIS, in order to prevent LRR. Women undergoing mas-
tectomy for DCIS should be counseled as to the potential
increased need for further surgical excision which affects
the final aesthetic outcome but lowers LRR. Further mul-
ticenter studies are necessary to evaluate LRR after SSM
and the role of post-reconstruction mammography to aid
earlier detection of LRR.
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TABLE 3 Analysis of univariate factors predicting risk of recurrence
Recurrence (n = 8) Non-recurrence (n = 191) HR (95% CI); p-value
Mean age, years (range) 48 (37–54) 57 (33–81) 0.92 (0.85–0.99); 0.028
Involved margins,\2 mm 5 52 4.39 (1.02–17.94); 0.046
High-grade 8 131 39.10 (0.085–18130.86); 0.241
Size, mm (range) 48 (20–80) 38 (1–90) 1.01 (0.99–1.04); 0.414
Microinvasion 25.0% 9.6% 2.21 (0.94–5.20); 0.067
Comedonecrosis 28.6% 22.8% 2.12 (0.75–6.00); 0.155
ER-negative 5 57 3.14 (0.75–13.13); 0.118
HER2-positive 83.3% 16.7% 1.66 (0.19–14.48); 0.644
Symptomatic presentation 25% 35% 0.62 (0.122–3.10); 0.56
1 Cox proportional hazard regression analysis
HR hazard ratio, CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2
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